Abbott Diagnostics Business competitors

Mr. Mazelsky was appointed President and Chief Executive Officer of IDEXX on October 23, 2019. Prior to his appointment, Mr. Mazelsky served as IDEXX's Interim President and Chief Executive Officer beginning on June 28, 2019. Prior to his appointment as Interim President and Chief Executive Officer, he was an Executive Vice President responsible for our North American Companion Animal Group Commercial Organization and key elements of the innovation portfolio, including our IDEXX VetLab® in-house diagnostics, Diagnostic Imaging, Veterinary Software and Services, Rapid Assay and Telemedicine lines of business. He joined IDEXX in August 2012 as Executive Vice President. Previously, Mr. Mazelsky was a Senior Vice President and General Manager from 2010 to 2012 of Computed Tomography, Nuclear Medicine and Radiation Therapy Planning at Philips Healthcare, a subsidiary of Royal Philips Electronics. Previously he held a series of other leadership roles with increasing responsibilities during his tenure at Philips beginning in 2001. Prior to joining Philips, Mr. Mazelsky was at Agilent Technologies, where he was an Executive in Charge from 2000 to 2002, leading the integration of Agilent’s Healthcare Group into Philips. He also served as a General Manager of the Medical Consumables Business Unit from 1997 to 2000 at Agilent Technologies. From 1988 to 1996, he was in a number of roles at Hewlett Packard in finance, marketing and business planning. Mr. Mazelsky holds a bachelor’s degree in mathematics from the University of Rochester and an M.B.A. from the University of Chicago.

Gary Guthart joined Intuitive Surgical in April 1996. Effective January 2010, Guthart was appointed as Chief Executive Officer. In July 2007, he was promoted to President. Prior to that, in February 2006, Guthart assumed the role of Chief Operating Officer. Prior to joining Intuitive, Guthart was part of the core team developing foundation technology for computer enhanced-surgery at SRI International (formerly Stanford Research Institute). Guthart is currently a member of the Board of Directors of Affymetrix, Inc. He received a B.S. in Engineering from the University of California, Berkeley and an M.S. and a Ph.D. in Engineering Science from the California Institute of Technology.

Joined Varian as an intern in 1999, then full time in 2001, and has held multiple cross-functional roles and executive positions during two-decade tenure with the company. Intimate understanding of healthcare, software solutions, medical devices, technology trends, reimbursement trends and strategies that lead to success in targeted channel segments globally. Marketing strategy, new product launch, portfolio strategy, M&A, P&L, restructuring, government relations, and general management experience. Consistent creation of strategies and execution against operating plans, sales goals and market objectives, including extensive experience of both high growth and slow growth periods (turnaround plans) of Varian Medical Systems journey from $500M to over $3B. Including returning Varian to double digit growth following becoming President of the $3B+ P&L of Oncology systems. Strong leadership skills with a track record of creating an inspiring vision and communicating effectively both internally/externally through developing cultural, servant leadership and focusing on people/teams to drive net promoter scores to all-time highs and enable sustainable long-term success.

President/CEO with proven track record of value creation and consistently delivering outstanding results amid challenging situations. Combines strong strategic mindset with a relentless focus on execution. Committed to developing high-performing teams and a winning culture. Experienced in leading capital equipment, disposables, and implantables businesses within public and private equity capital structures. Have transformed businesses and sold to strategic acquirers at attractive valuations.

A highly respected global business leader with 30 years of experience in personal care, beauty, food and beverage. Successful in leading turnaround businesses in US and European companies. Steward and builder of powerful global personal care brands including Dove, Axe, Vaseline, Ponds, and Degree. Led iconic confection brands including Hershey, Reese’s, and KitKat. High energy, purpose-driven leader with a proven track record, who builds diverse teams, cultivates leaders, and motivates teams to achieve transformational success. A bold decision maker and global change-agent who inspires growth through sound strategic vision, innovative consumer insight, and a passion for executional excellence.

Carlo Rosa is a CEO/General Manager at Diasorin, Board Member at Diasorin, and Chief Executive Officer at Diasorin GmbH. He has worked as Chief Operating Officer at Diasorin. Carlo works or has worked at Incstar Corp and works or has worked as Partner at Bioinvestment SA, Board Member at Sarago Srl, and Partner at Cid Investments Srl. He attended Unito.

Christophe Berthoux is an Exec VP:Global Sales & Mktg/Chief Commercial Ofcr at CHARLES RIVER LABORATORIES, Member of the Board of Directors at Synexus, and Chairman at IMAGE ANALYSIS INC and is based in London, Greater London, United Kingdom. He has worked as CEO at Synexus, Chief Executive Officer at Synexus Clinical Research Ltd, and Gen Mgr:Clinical Svcs at CHARLES RIVER LABORATORIES.

Founder of The Chopra Foundation, a non-profit entity for research on well-being and humanitarianism, and Chopra Global, a whole health company at the intersection of science and spirituality, is a world-renowned pioneer in integrative medicine and personal transformation. Chopra is a Clinical Professor of Family Medicine and Public Health at the University of California, San Diego and serves as a senior scientist with Gallup Organization.